Compare MGNI & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNI | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | MGNI | VERA |
|---|---|---|
| Price | $16.85 | $48.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $26.80 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 219.02 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $702,565,000.00 | N/A |
| Revenue This Year | $2.07 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | $44.27 | ★ N/A |
| Revenue Growth | ★ 6.27 | N/A |
| 52 Week Low | $8.22 | $18.53 |
| 52 Week High | $26.65 | $56.05 |
| Indicator | MGNI | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 58.17 |
| Support Level | $15.77 | $45.50 |
| Resistance Level | $17.41 | $56.05 |
| Average True Range (ATR) | 0.58 | 2.43 |
| MACD | 0.06 | -1.18 |
| Stochastic Oscillator | 61.89 | 31.28 |
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.